PTPN18 has been described to be expressed in breast cancer cells and implicated in diverse cellular functions, such as regulation of HER2 signaling, dynamic rearrangements of the cytoskeleton, and activation of the MYC-CDK4 axis [22, 24–26]. Here, ERBB2 is linked to breast carcinoma.